Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254760 | 0.94 | DRD2 (0.64) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL13609474 | 0.89 | DRD2 (0.60) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL9127008 | 0.89 | DRD2 (0.60) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL30380052 | 0.88 | TDP1 (0.64) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL16708685 | 0.88 | DRD2 (0.59) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL3524057 | 0.88 | DRD2 (0.66) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL23786468 | 0.87 | DRD2 (0.58) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL11014476 | 0.87 | DRD2 (0.58) | DRD2SIGMAR1TDP1MEN1GAA | |
| SCHEMBL4743239 | 0.86 | ACHE (0.58) | DRD2SIGMAR1TDP1MEN1GAA | |
| Iodide SCHEMBL15145961 | 0.86 | DRD2 (0.57) | DRD2SIGMAR1TDP1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2023059583-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | DRD2 3690/4885SIGMAR1 4785/4885TDP1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.